These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
68 related articles for article (PubMed ID: 1767512)
1. [Level of plasma fibronectin and its biological activity in patients with ovarian cancer]. Kharrasov AF; Safina NA; Moroz IP; Zinkevich OF Vopr Onkol; 1991; 37(5):572-6. PubMed ID: 1767512 [TBL] [Abstract][Full Text] [Related]
2. [Elevated expression of matrix metalloproteinase-9, and fibronectin concentration in recurrent epithelial ovarian cancer]. Demeter A; Szirmai K; Oláh J; Papp Z; Jeney A Orv Hetil; 2004 Aug; 145(31):1617-24. PubMed ID: 15384859 [TBL] [Abstract][Full Text] [Related]
3. Primary and metastatic ovarian cancer in patients with prior breast carcinoma. Pre-operative markers and treatment results. Tserkezoglou A; Kontou S; Hadjieleftheriou G; Apostolikas N; Vassilomanolakis M; Sikiotis K; Salamalekis E; Tseke P; Magiakos G Anticancer Res; 2006; 26(3B):2339-44. PubMed ID: 16821613 [TBL] [Abstract][Full Text] [Related]
4. [Dynamics of the plasma fibronectin level in patients with food poisoning]. Pak SG; Bogin IB; Kakhnovskaia NL; Sokurenko EV; Berchenko VV Ter Arkh; 1988; 60(11):71-5. PubMed ID: 3238583 [TBL] [Abstract][Full Text] [Related]
5. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors]. Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691 [TBL] [Abstract][Full Text] [Related]
6. Detection of serum transforming growth factor-alpha in patients of primary epithelial ovarian cancers by enzyme immunoassay. Chien CH; Huang CC; Lin YH; Shen J; Chow SN Gynecol Oncol; 1997 Sep; 66(3):405-10. PubMed ID: 9299253 [TBL] [Abstract][Full Text] [Related]
7. [Clinical significance of vascular endothelial growth factor in sera of patients with gynaecological malignant tumors]. Peng XP; Li JD; Li MD; Ye XM; Yan WC Ai Zheng; 2002 Feb; 21(2):181-5. PubMed ID: 12479072 [TBL] [Abstract][Full Text] [Related]
8. [The diagnostic value of the assay of lactate dehydrogenese combined with other tumor markers in ovarian cancer]. Tang BJ; Li L; Xu J Zhonghua Fu Chan Ke Za Zhi; 1994 Jun; 29(6):336-9, 381. PubMed ID: 8001406 [TBL] [Abstract][Full Text] [Related]
9. Afamin and apolipoprotein A-IV: novel protein markers for ovarian cancer. Dieplinger H; Ankerst DP; Burges A; Lenhard M; Lingenhel A; Fineder L; Buchner H; Stieber P Cancer Epidemiol Biomarkers Prev; 2009 Apr; 18(4):1127-33. PubMed ID: 19336561 [TBL] [Abstract][Full Text] [Related]
10. Preoperative plasma osteopontin level as a biomarker complementary to carbohydrate antigen 125 in predicting ovarian cancer. Nakae M; Iwamoto I; Fujino T; Maehata Y; Togami S; Yoshinaga M; Douchi T J Obstet Gynaecol Res; 2006 Jun; 32(3):309-14. PubMed ID: 16764622 [TBL] [Abstract][Full Text] [Related]
11. Preoperative tumor marker CA125 levels in relation to epithelial ovarian cancer stage. Fures R; Buković D; Hodek B; Klarić B; Herman R; Grubisić G Coll Antropol; 1999 Jun; 23(1):189-94. PubMed ID: 10402722 [TBL] [Abstract][Full Text] [Related]
12. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases. Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150 [TBL] [Abstract][Full Text] [Related]
13. [Cytokeratin tumor markers in ovarian carcinoma: tissue polypeptide specific antigen (TPS) and M3/M21]. Hefler L; Tempfer C; Häusler G; Heinzl H; Kainz C Wien Klin Wochenschr; 1998 Oct; 110(18):635-41. PubMed ID: 9816636 [TBL] [Abstract][Full Text] [Related]
14. [Quantitative and qualitative changes in the fibronectin level in rheumatoid arthritis]. Abdullin AR; Litvinov RI; Zinkevich OD; Salikov IG Ter Arkh; 1988; 60(4):89-94. PubMed ID: 3394105 [TBL] [Abstract][Full Text] [Related]
15. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients. Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388 [TBL] [Abstract][Full Text] [Related]
16. Quantification of total plasma cell-free DNA in ovarian cancer using real-time PCR. Kamat AA; Sood AK; Dang D; Gershenson DM; Simpson JL; Bischoff FZ Ann N Y Acad Sci; 2006 Sep; 1075():230-4. PubMed ID: 17108216 [TBL] [Abstract][Full Text] [Related]
17. A case control study of glycoprotein status in ovarian carcinoma. Aranganathan S; Senthil K; Nalini N Clin Biochem; 2005 Jun; 38(6):535-9. PubMed ID: 15885233 [TBL] [Abstract][Full Text] [Related]
18. [Plasmafibronectin in case of tumors of the female genital system]. Tatra G; Nasr F Strahlentherapie; 1983 Oct; 159(10):606-9. PubMed ID: 6417840 [TBL] [Abstract][Full Text] [Related]
19. Overexpression of epithelial macrophage colony-stimulating factor (CSF-1) and CSF-1 receptor: a poor prognostic factor in epithelial ovarian cancer, contrasted with a protective effect of stromal CSF-1. Chambers SK; Kacinski BM; Ivins CM; Carcangiu ML Clin Cancer Res; 1997 Jun; 3(6):999-1007. PubMed ID: 9815777 [TBL] [Abstract][Full Text] [Related]
20. Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Baron AT; Lafky JM; Boardman CH; Balasubramaniam S; Suman VJ; Podratz KC; Maihle NJ Cancer Epidemiol Biomarkers Prev; 1999 Feb; 8(2):129-37. PubMed ID: 10067810 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]